Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-alcoholic Steatohepatitis: Update Bulletin [June 2015]

Product Code:
596200388
Release Date:
June 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Non-alcoholic Steatohepatitis. Topics covered: Phase IIb FLINT trial of Intercept/Dainippon Sumitomo Pharma’s FXR agonist, obeticholic acid, in patients with NASH; obeticholic acid’s Phase III study design; Phase IIb GOLDEN-505 trial results for Genfit’s dual PPAR- alpha/delta agonist, elafibranor (GFT505); Phase II study results for Conatus Pharmaceuticals’ caspase protease inhibitor, emricasan; the potential of Zydus Cadila’s PPAR alpha/gamma agonist, saroglitazar (Lipaglyn); and the Phase II LEAN study results for Novo Nordisk’s GLP-1 receptor agonist liraglutide (Victoza/Saxenda).

Key Questions Answered in this Update Bulletin:

  • What impact do the updated subgroup analyses from the Phase IIb FLINT trial of Intercept/Dainippon Sumitomo Pharma’s obeticholic acid have on KOL perception of this agent?
  • How do KOLs view concomitant treatment with statins as a potential strategy to mitigate the LDL increases associated with obeticholic acid treatment?
  • What are KOLs views on the design of obeticholic acid’s Phase III trial, REGENERATE?
  • How do KOLs perceive the Phase IIb GOLDEN-505 trial results for Genfit’s elafibranor (GFT505)?
  • Are KOLs still optimistic about elafibranor’s potential as a future of treatment for NASH?
  • What are KOLs opinions of the Phase II study results for Conatus Pharmaceuticals’ caspase protease inhibitor, emricasan?
  • How do KOLs view the potential of Zydus Cadila’s PPAR alpha/gamma agonist, saroglitazar (Lipaglyn) as a treatment for NASH?
  • What do KOLs think about the results of the Phase II LEAN study for Novo Nordisk’s GLP-1 receptor agonist liraglutide (Victoza/Saxenda)?
  • In what treatment settings do KOLs anticipate liraglutide will have the greatest potential?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved